Literature DB >> 12444912

The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis.

Gerald F Watts1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12444912     DOI: 10.1042/cs1030595

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


× No keyword cloud information.
  4 in total

1.  Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein.

Authors:  Michael-Friedrich Boettcher; Roland Heinig; Carsten Schmeck; Christian Kohlsdorfer; Matthias Ludwig; Anja Schaefer; Sabine Gelfert-Peukert; Georg Wensing; Olaf Weber
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

Review 2.  Cholesteryl ester transfer protein and its inhibition.

Authors:  Olaf Weber; Hilmar Bischoff; Carsten Schmeck; Michael-Friedrich Böttcher
Journal:  Cell Mol Life Sci       Date:  2010-06-18       Impact factor: 9.261

Review 3.  Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.

Authors:  Teddy Kosoglou; Paul Statkevich; Amy O Johnson-Levonas; John F Paolini; Arthur J Bergman; Kevin B Alton
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules.

Authors:  Undurti N Das
Journal:  Lipids Health Dis       Date:  2008-10-15       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.